



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Ski, CF;Thompson, DR;Jackson, AC;Pedersen, SS

Title:

Psychological screening in cardiovascular care

Date:

2025-05-01

Citation:

Ski, C. F., Thompson, D. R., Jackson, A. C. & Pedersen, S. S. (2025). Psychological screening in cardiovascular care. *European Journal of Cardiovascular Nursing*, 24 (4), pp.647-651. <https://doi.org/10.1093/eurjcn/zvaf057>.

Persistent Link:

<https://hdl.handle.net/11343/361821>

License:

[CC BY-NC](#)

# Psychological screening in cardiovascular care

Chantal F. Ski <sup>1,2\*</sup>, David R. Thompson <sup>1,2</sup>, Alun C. Jackson <sup>2,3</sup>, and  
Susanne S. Pedersen <sup>4,5</sup>

<sup>1</sup>School of Nursing and Midwifery, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK; <sup>2</sup>Australian Centre for Heart Health, 75-77 Chetwynd St, North Melbourne, VIC 3051, Australia; <sup>3</sup>Melbourne School of Psychological Sciences, University of Melbourne, Parkville, VIC 3010, Australia; <sup>4</sup>Department of Psychology, University of Southern Denmark, Campusvej 55, Odense, OdenseM, DK-5230, Denmark; and <sup>5</sup>Department of Cardiology, Odense University Hospital, J.B. Winsloews Vej, Odense, Odense C-5000, Denmark

Received 20 February 2025; revised 28 March 2025; accepted 29 March 2025; published 4 April 2025

Approximately one in three patients with cardiovascular disease experience psychological distress, often with an associated poor prognosis. Early detection and intervention can improve patients' heart and mental health, yet minimal guidance on psychological screening is offered for clinicians working in cardiovascular care. This paper describes a pragmatic approach to conducting psychological screening during routine clinical care, including when and how to screen and what to do in the case of a positive screen. A psychological screening protocol is proposed to enable clinicians to assess and, where necessary, intervene or refer for further evaluation.

## Keywords

Cardiovascular care • Psychological screening • Screening protocol

## Highlights

- Screening for common psychological conditions in patients with cardiovascular disease is recommended internationally, though minimal guidance is offered to clinicians not trained in mental health.
- Considerable evidence attests to a bi-directional relationship between heart and mind, with anxiety and depression being particularly prevalent and though screening is important, alone is insufficient to improve health outcomes.
- To address these gaps practical guidance on screening in routine cardiovascular care is offered, as well as simple steps to take in the case of positive screens.
- Psychological screening can be easily incorporated into routine clinical care, with early detection increasing the potential for improved heart and mental health.

## Background

Psychological conditions occur frequently in individuals with cardiovascular disease (CVD) and are associated with poor prognosis. For example, global prevalence rates have been estimated at 31% for depression, 33% for anxiety, and 58% for stress in cardiac patients.<sup>1</sup> These comorbidities have been shown to negatively impact self-management,<sup>2</sup> treatment adherence,<sup>3</sup> health-related quality of life,<sup>4,5</sup> morbidity and mortality,<sup>6–8</sup> and to significantly increase health care costs.<sup>9–11</sup> These findings have led to screening for psychological conditions being included in guidelines for CVD prevention, management and

rehabilitation worldwide.<sup>12–16</sup> Despite this, such screening in clinical practice remains suboptimal.<sup>17–21</sup>

With the burden of mental health increasing globally<sup>22,23</sup> and screening for such conditions in patients with CVD on the decline,<sup>19</sup> clinicians face a heightened need to prioritize treating the person as a whole, not just the physical disease. Numerous scientific data attest to the causal links between psychological functioning and CVD, as well as a bi-directional relationship.<sup>5,24–28</sup> For example, patients with heart disease have been shown to have a 1.79-fold increased risk of depression, and patients with depression have a 1.63-fold increased risk of heart disease independent of shared risk factors such as body mass index, lifestyle,

\* Corresponding author. Email: [c.ski@qub.ac.uk](mailto:c.ski@qub.ac.uk)

© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [reprints@oup.com](mailto:reprints@oup.com) for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

socioeconomic status, serum lipids and statin use.<sup>27</sup> Importantly, mounting evidence shows that early recognition of behavioural health disorders can lower CVD risk,<sup>13,28</sup> prevent complications<sup>7,20</sup> and reduce healthcare costs.<sup>9,11</sup> However, whilst cardiovascular care may enable early identification of patients at high risk of mental health, many clinicians without formal training in mental health feel ill-equipped to undertake psychological screening.<sup>5,18,29</sup> In this paper we outline a practical approach for screening of the most prevalent mental health conditions, such as anxiety, depression and distress in the clinical setting for patients with CVD.

## Key considerations for psychological screening

Rapid screening of mental health conditions has been identified as an efficient approach to understanding an individual's overall CVD risk profile, enabling early access to, and more personalized, treatment options, thus increasing potential for better patient health outcomes.<sup>7,13,20</sup> Despite the evidence, minimal guidance is offered to non-psychologically trained cardiovascular care clinicians on psychological screening, including which screening tools to use, when to screen, and how often to screen.<sup>20,30</sup> For psychological screening to be integrated into usual clinical practice with minimum interference and maximum benefit, consideration should be given to:

- (1) When to screen.
- (2) How to screen.
- (3) What to do with a positive screen.

### When to screen

To provide optimal cardiovascular care, early identification of mental health symptoms is recommended.<sup>8,13–15,20</sup> Thus, screening should ideally take place at the first clinical encounter, and at subsequent follow-up appointments, usually at 2–3 months post-cardiac event.<sup>13</sup> Unless indicated by the patient, screening should then be considered on a yearly basis, as for any other major risk factor for CVD.<sup>13</sup>

### How to screen

#### Choice of screening tool

The primary consideration when choosing an appropriate screening tool is its suitability for administration in routine clinical practice.<sup>31</sup> Ideally, the screening tool should be user-friendly and brief. Awareness of health literacy is an important consideration,<sup>32,33</sup> and the screening tool should be easily understood and in plain, non-medical language. Also, due to time constraints, administration and scoring should take no more than a few minutes, and preferably be communicated/administered verbally.<sup>31,34</sup> Consideration should also be given to accessibility, e.g. does permission need to be gained for use? Is it copyrighted? Are there costs involved with administration or scoring? Can it be administered with minimal training? Lastly, and most importantly, the screening tool should have demonstrated sound psychometric properties pertaining to the target population.<sup>31,35</sup> In other words, has it been shown to be a reliable and valid instrument when used on patients with CVD? By addressing each of these considerations, the likelihood of psychological screening serving as a cost-effective measure to reduce risk and mitigate any further complications is increased.

#### Common screening tools

The Generalized Anxiety Disorder-2 item (GAD-2)<sup>36</sup> and the Patient Health Questionnaire-2 item (PHQ-2)<sup>37,38</sup> are screening tools for anxiety and depression deemed fit for purpose. Adhering to each of the above outlined considerations, the GAD-2 and the PHQ-2 are easily

**Table 1** PHQ-4: initial screen

Over the last 2 weeks, how often have you been bothered by any of the following problems?	Not at all	Several days	More than half the days	Nearly every day
<b>(GAD-2)</b>				
1. Feeling nervous, anxious, or on edge	0	1	2	3
2. Not being able to stop or control worrying	0	1	2	3
<b>(PHQ-2)</b>				
3. Have you had little interest or pleasure in doing things?	0	1	2	3
4. Have you been feeling down, depressed or hopeless?	0	1	2	3


**Nb.** GAD-2, Generalized Anxiety Disorder-2 item<sup>36</sup>; PHQ-2, Patient Health Questionnaire-2 item<sup>37</sup>.

accessible, user-friendly, brief, and have been recommended for use in routine cardiovascular care.<sup>13,39</sup> Furthermore, anxiety and depression are two of the most prevalent psychological conditions in patients with CVD<sup>1</sup> and both the GAD-2 and the PHQ-2 have sound psychometric properties in CVD populations.<sup>5,13,20,39</sup> When used in conjunction, these four questions are well-validated and known as the PHQ-4 (Table 1).<sup>40</sup>

For patients with CVD who screen positive using the GAD-2 (score  $\geq 1$ )<sup>39</sup> or PHQ-2 (score  $\geq 2$ ),<sup>41,42</sup> recommended is a two-step procedure with follow-up using the 7-item GAD-7 and 9-item PHQ-9 respectively.<sup>13,36,43</sup> Both the GAD-7 and PHQ-9 take about 3 minutes to complete, can be easily incorporated into routine care, have shown reasonable sensitivity and specificity, and predict worse outcomes in patients with CVD.<sup>36,44</sup>

#### Other screening tools

In consideration of the high prevalence of co-existing psychological conditions in patients with CVD, e.g. a three-fold increased likelihood of CVD in patients with comorbid anxiety and depression,<sup>45</sup> alternative well-validated tools are available. The Hospital Anxiety and Depression Scale (HADS), for example, is a rapid self-report instrument specifically constructed for physically ill patients<sup>46</sup> that has been validated and used extensively with patients with CVD and is easy to administer and score.<sup>47,48</sup> The HADS measures symptoms of anxiety (HADS-A; 7 items) and depression (HADS-D; 7 items) with items rated on a 4-point (0–3) scale (cut-off scores  $>7$  indicate possible;  $>10$  indicate probable depression or anxiety). However, the HADS is subject to licensing fees.<sup>46</sup> Further acknowledging the complexity of distress commonly experienced post-cardiac event, a new tool has been developed, the Cardiac Distress Inventory (CDI).<sup>49</sup> This is a disease-specific clinical assessment tool that spans multiple psychosocial domains, thereby incorporating patients responses to physical, affective, cognitive, behavioural and social symptoms and experiences related to their cardiac event and recovery.<sup>50</sup> The short-form version—CDI-SF—consists of



12-items that provides a brief psychometrically sound screening measure of cardiac distress that can be used in both clinical and research settings (cut-off score >13 indicate need for referral) and is available free of charge.<sup>51</sup>

### What to do with a positive screen

Regardless of the screening tool used, it is important to acknowledge that screening alone is not sufficient without appropriate referral or treatment.<sup>5,13,20,52</sup> Timely diagnosis combined with multidisciplinary management has the potential to enable not only early detection, but also to achieve optimal patient outcomes.<sup>7,20,53</sup> Additionally, screening can be used as the basis for more sensitive discussions during a clinical encounter, including signalling to patients the significance of treating the heart and mind together. These brief, targeted discussions can be highly effective in addressing issues such as the impact of mental health symptoms on adherence and physical function, and the importance of referral to mental health services. Of note, such discussions are often highly valued by patients.<sup>5,20,54</sup> Furthermore, it is important to have a follow-up plan for patients who screen positive, one that, where possible, involves multidisciplinary integrated care pathways for referral and assessment.

### Psychological screening protocol

A psychological screening protocol that promotes patient education, early detection and referral can be highly effective.<sup>31</sup> The protocol should be simple and adaptable, dependent on linked mental health services and resources. In its most basic form, the screening protocol would comprise a psychological screen, patient education, and a referral pathway *central illustration*.

### Psychological screen

In the first instance, as recommended in consensus statements and guidelines, a two-step screening procedure could be implemented administering the PHQ-2 and/or the GAD-2. Then for those who screen positive, this would be followed-up using the PHQ-9 and/or the GAD-7 to confirm the positive screen. Essential to the screen is to have clearly specified cut-off scores for each screening tool administered for the purpose of referral.

### Patient education

A positive screen is an ideal way of introducing the patient to a holistic care approach; care that involves treating their heart as well as their mental health. However, it is also important to be mindful that caring for the patient with CVD involves management of multiple risk factors, not only psychological ones. Thus, in the clinical encounter, patient education should be concise and succinct, with the purpose of introducing the relationship that exists between heart and mind, i.e. engaging in brief discussions post-screening, and providing educational materials and links to community and online mental health resources and supports. Alternatively, the importance of psychological screening can be discussed prior to performing screening, which can also lead to increased patient acceptability.<sup>33</sup> Further, some patients may not be used to talking about their mental health; thus, fostering a collaborative and sensitive discussion with them is essential for creating an environment in which patients feel safe and their perspectives valued. Although brief, effective communication that increases patient awareness of maintaining good mental health can additionally foster patient-centeredness, enhance shared decision-making and increase patient satisfaction.<sup>20,33,53,54</sup>

## Referral pathway

Though screening can provide an early indication of mental health symptoms, more testing is required to diagnose a specific psychological condition. Thus, following a positive psychological screen, the patient should then be referred to a clinician with mental health training, usually to a psychologist, for diagnostic assessment.<sup>13,14,20,52,53</sup> Ideally, an integrated multidisciplinary approach should be considered whereby the management of patients with psychological conditions is facilitated through collaborative care.<sup>20,31</sup> Referral pathways may already be in place, either to psychological services or community mental health services. If not, dependent on resource availability, it is advisable that such referral pathways are initiated. Appropriate referral and accurate diagnosis can provide critical insights into the mechanisms and strategies for targeted interventions. Robust data demonstrate the effectiveness of psychological interventions for improving mental health and reducing cardiovascular risk.<sup>55,56</sup>

Although psychological screening will take some time to conduct in busy cardiovascular care environments, if issues are identified and a protocol is in place, investment in such time spent is likely to yield benefits such as, treatment adherence, satisfaction, better quality of life and improved patient health outcomes.

## Conclusion

Around one in three patients with CVD experience psychological distress. Cardiovascular healthcare professionals can play a crucial role in detecting such distress by conducting psychological screening during routine clinical encounters. A psychological screening protocol can aid the process and empower clinicians to assess and, where necessary, intervene or refer patients for further evaluation. Moreover, psychological screening can potentially improve therapeutic adherence and clinical outcomes.

## Author contributions

C.F.S.: conceptualisation, writing—original draft preparation; All authors writing—reviewing and editing. C.F.S., D.R.T., A.C.J., and S.S.P.

## Funding

Not applicable. The project is part of our expected work tasks at our institution.

**Conflicts of interest:** C.F.S. is a member of the Editorial Board and D.R.T. is a Senior Consulting Editor for the *European Journal of Cardiovascular Nursing*.

## Data availability

There are no data available. This is a discussion paper using existing accessible sources and author perspectives.

## References

- Karami N, Kazemina M, Karami A, Salimi Y, Ziapour A, Janjani P. Global prevalence of depression, anxiety, and stress in cardiac patients: a systematic review and meta-analysis. *J Affect Disord* 2023;**324**:175–189.
- Cilli E, Ranieri J, Guerra F, Ferri C, Di Giacomo D. Cardiovascular disease, self-care and emotional regulation processes in adult patients: balancing unmet needs and quality of life. *Biopsychosoc Med* 2022;**16**:20.
- Glazer KM, Emery CF, Frid DJ, Banyasz RE. Psychological predictors of adherence and outcomes among patients in cardiac rehabilitation. *J Cardiopulm Rehabil* 2002;**22**:40–46.
- Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. *Am J Hypertens* 2015;**28**:1295–1302.
- Levine GN, Cohen BE, Commodore-Mensah Y, Fleury J, Huffman JC, Khalid U, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. *Circulation* 2021;**143**:e763–e783.

- Emdin CA, Odutayo A, Wong CX, Tran J, Hsiao AJ, Hunn BH. Meta-analysis of anxiety as a risk factor for cardiovascular disease. *Am J Cardiol* 2016;**118**:511–519.
- Gaffey AE, Gathright EC, Fletcher LM, Goldstein CM. Screening for psychological distress and risk of cardiovascular disease and related mortality: a systematized review, meta-analysis, and case for prevention. *J Cardiopulm Rehabil Prev* 2023;**43**:73.
- Krittanawong C, Maitra NS, Qadeer YK, Wang Z, Fogg S, Storch EA, et al. Association of depression and cardiovascular disease. *Am J Med* 2023;**136**:881–895.
- Tápias FS, Otani VHO, Vasques DAC, Otani TZS, Uchida RR. Costs associated with depression and obesity among cardiovascular patients: medical expenditure panel survey analysis. *BMC Health Serv Res* 2021;**21**:433.
- Wang G, Park C, Joo H, Hawkins N, Fang J. Depression and medical cost of cardiovascular diseases. *Innov Aging* 2019;**3**:S497.
- Thyagaturu H, Abdelhadi O, Younas H, Abugrin M, Padala V, Atti L, et al. Psychological distress in adults with myocardial infarction: implications for healthcare utilization and expenditure. *JACC Adv* 2025;**4**:101540.
- British Association for Cardiovascular Prevention and Rehabilitation (BACPR). *The BACPR Standards and Core Components for Cardiovascular Disease Prevention and Rehabilitation* 2023. 4th ed. London: British Cardiovascular Society; 2023.
- Colquhoun DM, Bunker SJ, Clarke DM, Glozier N, Hare DL, Hickie IB, et al. Screening, referral and treatment for depression in patients with coronary heart disease. *Med J Aust* 2013;**198**:483–484.
- National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. 2022. (NICE Guideline, No. 222). <https://www.nice.org.uk/guidance/ng222> (29 January 2025).
- Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2016;**37**:2315–2381.
- Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Böck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). *Eur Heart J* 2021;**42**:3227–3337. Corrigendum: *Eur Heart J* 2022;**43**:4468. doi: 10.1093/eurheartj/ehac458.
- Blatch Armon D, Buhayer A, Dobretz K, Mach F, Meinschmidt G, Battagay E. Practice guidelines for cardiovascular disease: how is depression addressed? *Eur Heart J* 2023;**44**:ehad655.2383.
- Collopy CM, Cosh SM, Tully PJ. Screening and referral is not enough: a qualitative exploration of barriers to access and uptake of mental health services in patients with cardiovascular diseases. *BMC Health Serv Res* 2021;**21**:49.
- Helmark C, Harrison A, Pedersen SS, Doherty P. Screening for—and prevalence of— anxiety and depression in cardiac rehabilitation in the post-COVID era. An observational study. *Int J Cardiol* 2023;**393**:131379.
- Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrrough JW. Screening and management of depression in patients with cardiovascular disease: JACC State-of-the-Art Review. *J Am Coll Cardiol* 2019;**73**:1827–1845.
- Jackson AC, Le Grande MR, Higgins RO, Rogerson M, Murphy BM. Psychosocial screening and assessment practice within cardiac rehabilitation: a survey of cardiac rehabilitation coordinators in Australia. *Heart Lung Circ* 2017;**26**:64–72.
- Su Z, Bentley BL, McDonnell D, Segalo S, Jiang J, Yu X, et al. Global mental health solidarity: strategies and solutions. *Discov Ment Health* 2024;**4**:40.
- Wu Y, Wang L, Tao M, Cao H, Yuan H, Ye M, et al. Changing trends in the global burden of mental disorders from 1990 to 2019 and predicted levels in 25 years. *Epidemiol Psychiatr Sci* 2023;**32**:e63.
- Bergstedt J, Pasman JA, Ma Z, Harder A, Yao S, Parker N, et al. Distinct genomic signatures and modifiable risk factors underly the comorbidity between major depressive disorder and cardiovascular disease. *Nat Cardiovasc Res* 2024;**3**:754–769.
- Shao M, Lin X, Jiang D, Tian H, Xu Y, Wang L, et al. Depression and cardiovascular disease: shared molecular mechanisms and clinical implications. *Psychiatry Res* 2020;**285**:112802.
- Borkowski P, Borkowska N. Understanding mental health challenges in cardiovascular care. *Cureus* 2024;**16**:e54402.
- Wium-Andersen MK, Wium-Andersen IK, Prescott EIB, Overvad K, Jørgensen MB, Osler M. An attempt to explain the bidirectional association between ischaemic heart disease, stroke and depression: a cohort and meta-analytic approach. *Br J Psychiatry* 2020;**217**:434–441.
- Sokoreli I, de Vries JJ, Riistama JM, Pauws SC, Steyerberg EW, Tesanovic A, et al. Depression as an independent prognostic factor for all-cause mortality after a hospital admission for worsening heart failure. *Int J Cardiol* 2016;**220**:202–207.
- Peltzer S, Müller H, Köstler U, Schulz-Nieswandt F, Jessen F, Albus C, et al. Detection and treatment of mental disorders in patients with coronary heart disease (MenDis-CHD): a cross-sectional study. *PLoS One* 2020;**15**:e0243800.
- Thompson DR, Pedersen SS. Psychosocial assessment and psychological interventions following a cardiac event. *Heart* 2023;**109**:405–410.

31. Mulvaney-Day N, Marshall T, Downey Piscopo K, Korsen N, Lynch S, Karnell LH, et al. Screening for behavioral health conditions in primary care settings: a systematic review of the literature. *J Gen Intern Med* 2018;**33**:335–346.
32. Woringner M, Nielsen JJ, Zibarras L, Evason J, Kassianos AP, Harris M, et al. Development of a questionnaire to evaluate patients' awareness of cardiovascular disease risk in England's National Health Service Health check preventive cardiovascular programme. *BMJ Open* 2017;**7**:e014413.
33. Beauchamp A, Sheppard R, Wise F, Jackson A. Health literacy of patients attending cardiac rehabilitation. *J Cardiopulm Rehabil Prev* 2020;**40**:249–254.
34. Albus C, Jordan J, Herrmann-Lingen C. Screening for psychosocial risk factors in patients with coronary heart disease—recommendations for clinical practice. *Eur J Cardiovasc Prev Rehabil* 2004;**11**:75–79.
35. Boateng GO, Neilands TB, Frongillo EA, Melgar-Quiñonez HR, Young SL. Best practices for developing and validating scales for health, social, and behavioral research: a primer. *Front Public Health* 2018;**6**:149.
36. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic meta-analysis. *Gen Hosp Psychiatry* 2016;**39**:24–31.
37. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. *J Gen Intern Med* 1997;**12**:439–445.
38. Kroenke K, Spitzer RL, Williams JB. The patient health questionnaire-2: validity of a two-item depression screener. *Med Care* 2003;**41**:1284–1292.
39. Celano CM, Suarez L, Mastromauro C, Januzzi JL, Huffman JC. Feasibility and utility of screening for depression and anxiety disorders in patients with cardiovascular disease. *Circ Cardiovasc Qual Outcomes* 2013;**6**:498–504.
40. Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. *Psychosomatics* 2009;**50**:613–621.
41. Pedersen SS, Denollet J, de Jonge P, Simsek C, Serruys PW, van Domburg RT. Brief depression screening with the PHQ-2 associated with prognosis following percutaneous coronary intervention with paclitaxel-eluting stenting. *J Gen Intern Med* 2009;**24**:1359.
42. Thombs BD, Ziegelstein RC, Whooley MA. Optimizing detection of major depression among patients with coronary artery disease using the patient health questionnaire: data from the heart and soul study. *J Gen Intern Med* 2008;**23**:2014–2017.
43. Lichtman JH, Bigger JT Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. *Circulation* 2008;**118**:1768–1775.
44. Bolgeo T, Di Matteo R, Simonelli N, Dal Molin A, Lusignani M, Bassola B, et al. Psychometric properties and measurement invariance of the 7-item General Anxiety Disorder scale (GAD-7) in an Italian coronary heart disease population. *J Affect Disord* 2023;**334**:213–219.
45. Vogelzangs N, Seldenrijk A, Beekman AT, van Hout HP, de Jonge P, Penninx BV. Cardiovascular disease in persons with depressive and anxiety disorders. *J Affect Disord* 2010;**125**:241–248.
46. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;**67**:361–370.
47. Tesio V, Molinaro S, Castelli L, Andriani M, Fanelli AL, Marra S, et al. Screening of depression in cardiac patients: is the HADS an effective tool? *Int J Cardiol* 2014;**172**:e344–e345.
48. Bambauer KZ, Locke SE, Auport O, Mullan MG, McLaughlin TJ. Using the Hospital Anxiety and Depression Scale to screen for depression in cardiac patients. *Gen Hosp Psychiatry* 2005;**27**:275–284.
49. Jackson AC, Rogerson MC, Amerena J, Smith J, Hoover V, Alvarenga ME, et al. Unravelling the complexity of cardiac distress: a study of prevalence and severity. *Front Psychiatry* 2022;**13**:808904.
50. Jackson AC, Murphy BM, Thompson DR, Ski CF, Alvarenga ME, Le Grande MR, et al. What is cardiac distress and how should we measure it? *Br J Card Nurs* 2018;**13**:286–293.
51. Le Grande MR, Murphy BM, Rogerson MC, Ski CF, Amerena J, Smith JA, et al. Development of a short form of the cardiac distress inventory. *BMC Cardiovasc Disord* 2023;**23**:408.
52. Ski CF, Worrall-Carter L, Cameron J, Castle DJ, Rahman MA, Thompson DR. Depression screening and referral in cardiac wards: a 12-month patient trajectory. *Eur J Cardiovasc Nurs* 2017;**16**:157–166.
53. Ski CF, Munian S, Rolley JX, Thompson DR. Evaluation of nurses' perceptions of the impact of targeted depression education and a screening and referral tool in an acute cardiac setting. *J Clin Nurs* 2015;**24**:235–243.
54. Murphy BM, Higgins RO, Jackson AC, Edington J, Jackson A, Worcester MU. Patients want to know about the 'cardiac blues'. *Aust Fam Physician* 2015;**44**:826–832.
55. El Baou C, Desai R, Cooper C, Marchant NL, Pilling S, Richards M, et al. Psychological therapies for depression and cardiovascular risk: evidence from national healthcare records in England. *Eur Heart J* 2023;**44**:1650–1662.
56. Ski CF, Taylor RS, McGuigan K, Long L, Lambert JD, Richards SH, et al. Psychological interventions for depression and anxiety in patients with coronary heart disease, heart failure or atrial fibrillation. *Cochrane Database Syst Rev* 2024;**4**:CD013508.